Roberta Laís Mendonça de Mattos1, Danilo Toshio Kanno1, Fábio Guilherme Campos2, Geovanna Pacciulli Pereira3, Mateus Magami Yoshitani3, Andress de Godoy Delben4, José Aires Pereira5, Carlos Augusto Real Martinez1,6. 1. Post-Graduate Program in Healt Sciences, São Francisco University Medical School, Bragança Paulista, São Paulo, Brazil. 2. Department of Gastroenterology, Faculty of Medicine, Universidade de São Paulo, São Paulo, Brazil. 3. Faculty of Medicine, São Francisco University Medical School, Bragança Paulista, São Paulo, Brazil. 4. Post-Graduate Program in Sciences of Surgery, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil. andress2003@gmail.com. 5. Department of Pathology, São Francisco University Medical School, Bragança Paulista, São Paulo, Brazil. 6. Department of Surgery, Campinas State University, Campinas, Brazil.
Abstract
BACKGROUND: Metastasis is the worst prognostic variable of patients with colorectal cancer (CRC). For the development of metastases, it is necessary that cancer cells detach from the primary tumor, migrate into the angiolymphatic system, and invade the tissue where they will develop. The breakdown of the tight junctions (TJs) plays an important role in colorectal metastatic tumors. Claudin-3 and occludin are the main component proteins of TJs. AIM: To analyze the expression and tissue content of claudin-3 and occludin in normal and neoplastic tissues of patients with metastatic CRC. METHODS: Fifty-seven consecutive patients with stage III and IV CRC were included. Fragments of neoplastic tissue were collected from the tumor margins, and samples of the normal tissue were collected from the same patient in a standardized distance of 10 cm from the cranial margin of the tumor. Immunohistochemistry technique was used to identify the tissue staining of claudin-3 and occludin. To measure the content of both proteins in cellular membranes of normal and cancer cells, a validated immunoscore was used. RESULTS: Claudin-3 and occludin in normal tissues are in the apical and lateral membranes of cells, while in the neoplastic, in cytoplasm. The mean of the tissue content of claudin-3 in the normal tissue was 2.57 ± 0.16, while in the neoplastic tissue was 1.03 ± 0.13. The contents of occludin were 2.77 ± 0.1 in normal tissue, while in the neoplastic were 1.08 ± 0.14. CONCLUSION: There is a reduction in the content of the claudin-3 and occludin in the cell membranes of the neoplastic tissue in patients with CRC.
BACKGROUND: Metastasis is the worst prognostic variable of patients with colorectal cancer (CRC). For the development of metastases, it is necessary that cancer cells detach from the primary tumor, migrate into the angiolymphatic system, and invade the tissue where they will develop. The breakdown of the tight junctions (TJs) plays an important role in colorectal metastatic tumors. Claudin-3 and occludin are the main component proteins of TJs. AIM: To analyze the expression and tissue content of claudin-3 and occludin in normal and neoplastic tissues of patients with metastatic CRC. METHODS: Fifty-seven consecutive patients with stage III and IV CRC were included. Fragments of neoplastic tissue were collected from the tumor margins, and samples of the normal tissue were collected from the same patient in a standardized distance of 10 cm from the cranial margin of the tumor. Immunohistochemistry technique was used to identify the tissue staining of claudin-3 and occludin. To measure the content of both proteins in cellular membranes of normal and cancer cells, a validated immunoscore was used. RESULTS: Claudin-3 and occludin in normal tissues are in the apical and lateral membranes of cells, while in the neoplastic, in cytoplasm. The mean of the tissue content of claudin-3 in the normal tissue was 2.57 ± 0.16, while in the neoplastic tissue was 1.03 ± 0.13. The contents of occludin were 2.77 ± 0.1 in normal tissue, while in the neoplastic were 1.08 ± 0.14. CONCLUSION: There is a reduction in the content of the claudin-3 and occludin in the cell membranes of the neoplastic tissue in patients with CRC.
Authors: Carlos Augusto Real Martinez; Fabio Guilherme Caserta Maryssael de Campos; Viviel Rodrigo José de Carvalho; Caroline de Castro Ferreira; Murilo Rocha Rodrigues; Daniela Tiemi Sato; José Aires Pereira Journal: J Mol Histol Date: 2015-02-04 Impact factor: 2.611
Authors: R Ahmad; B Kumar; Z Chen; X Chen; D Müller; S M Lele; M K Washington; S K Batra; P Dhawan; A B Singh Journal: Oncogene Date: 2017-08-07 Impact factor: 9.867
Authors: Jonathan Landy; Emma Ronde; Nick English; Sue K Clark; Ailsa L Hart; Stella C Knight; Paul J Ciclitira; Hafid Omar Al-Hassi Journal: World J Gastroenterol Date: 2016-03-21 Impact factor: 5.742